Valuation is based on a sustainable EV/EBITDA multiple of ~20x applied to FY27 guided EBITDA ($320M midpoint), reflecting high quality, defensible SaaS margins and platform optionality, but discounting peak multiples. Cash of $688M and no debt support capital flexibility. Share count of 210M is mos…
Doximity (DOCS) Q1 2027: AI Scribe Usage Jumps 10x, Unlocking Platform Leverage
Doximity’s Q1 marked a strategic inflection as clinical AI adoption surged and platform monetization broadened. Leadership’s deliberate AI investment is yielding rapid workflow integration and deeper enterprise traction, while new AI search and scribe products are catalyzing both usage and commercial pipeline expansion. With pharma and hospital clients signaling growing engagement, Doximity is positioned to accelerate AI-driven growth as the year progresses.
Summary
- AI Workflow Adoption Surges: Clinician engagement with AI tools is driving new platform stickiness and usage highs.
- Commercial Pipeline Expands: New AI search contracts and hospital wins are fueling cross-segment momentum.
- Margin Leadership Funds Innovation: High software margins enable aggressive AI investment without sacrificing profitability.
Business Overview
Doximity operates as the digital platform for U.S. medical professionals, offering workflow, networking, news, telehealth, and clinical decision support tools. The company monetizes through subscription-based marketing and workflow solutions sold to pharmaceutical companies and health systems, with a growing focus on AI-powered products like Doximity Ask (clinical AI search) and Scribe (AI note-taking). Its two primary customer segments—pharma and hospital/health systems—account for the majority of revenue, with large enterprise contracts driving 83% of sales.
Performance Analysis
Doximity delivered a notable reacceleration in revenue growth, underpinned by robust adoption of its clinical AI suite and stabilization in the pharma marketing environment. The company’s largest customers—127 pharma and hospital accounts generating over $500,000 annually—remained the core revenue engine, contributing 83% of total sales. Net revenue retention among the top 20 customers stood at 112%, reflecting both upsell and stickiness in the installed base.
AI is now a material driver of both usage and future monetization. Workflow prescriber activity climbed over 30% year-on-year, with nearly half of these clinicians leveraging AI tools, and AI prompt volume jumped more than 25% sequentially. The AI Scribe product saw a 10x user increase in July alone, signaling rapid workflow embedment. While AI search revenue was not recognized in Q1, contracted deals and a growing pipeline point to a revenue ramp in the second half. Gross margin compressed to 88% (from 91%) as compute and AI spend scaled, but EBITDA margins remained best-in-class at 48%.
- AI Compute Investment: Elevated AI usage drove higher cost of revenue, but management expects margin normalization as models improve.
- Pharma Spend Rebounds: Innovation budgets are opening, with AI search unlocking new customer conversations and budget pools.
- Share Repurchases: $92 million in buybacks reflect confidence and capital discipline amid ongoing investment.
With $688 million in cash and no debt, Doximity maintains ample capacity to fund its AI roadmap and opportunistic capital returns.
Executive Commentary
"We're proving you can still post best in class software margins while investing heavily in clinical AI. We're leaning in as we see a once-in-a-generation opportunity to build the new AI age of medicine."
Jeff Tangney, Co-founder and CEO
"Higher than expected AI usage creates a good problem for Doximity and will expand our AI investment in fiscal 27 to capture the significant long-term opportunity ahead."
Matt Sonfeld, Chief Financial Officer
Strategic Positioning
1. Clinical AI Leadership through Safety and Accuracy
Doximity Ask, clinical AI search, topped independent benchmarks, posting the lowest error rates among U.S. models. This is attributed to its integrated, expert-verified drug reference and a peer review network of 12,000 physician editors. These safeguards are crucial for hospital AI steering committees, positioning Doximity as the trusted enterprise partner as the market shifts from individual to institutional AI adoption.
2. Expanding Enterprise Penetration and Workflow Integration
With 165 health system AI clients, including top-tier hospitals like Northwestern and Penn Medicine, Doximity is embedding its AI suite into clinical workflows. The company’s platform approach—integrating telehealth, Scribe, and Ask—creates a sticky, multi-product footprint that aligns with health system preferences for comprehensive, secure solutions over point tools.
3. Commercial AI Monetization and Pipeline Development
AI Search monetization is catalyzing new pharma engagement, with two dozen contracted programs and a robust pipeline for FY27. Early contracts were deliberately capped to optimize user experience and product iteration, but management plans to shift toward larger, longer-term deals and broader therapeutic coverage as the product matures. The AI search product is expected to generate revenue at attractive unit economics, with revenue per search already exceeding cost by 10x.
4. Product-Led Growth and Cross-Sell Synergy
AI solutions are unlocking cross-sell opportunities, as higher-level conversations with pharma and hospital CXOs translate into bundled deals across legacy and new offerings. The integration of Scribe and Ask is envisioned as the foundation of a “doctor’s digital assistant,” with Doximity uniquely positioned as a top-three player in both note-taking and decision support.
Key Considerations
This quarter marks a pivotal transition from AI experimentation to scaled enterprise deployment and monetization. Doximity is leveraging its platform breadth, physician trust, and margin profile to extend its lead in clinical AI while broadening its revenue base.
Key Considerations:
- AI Usage Outpaces Expectations: Record clinician adoption is accelerating both product innovation and commercial opportunity.
- Enterprise Decision-Making Accelerates: Hospitals are shifting from fragmented AI adoption to standardized, privacy-focused solutions, favoring Doximity’s integrated model.
- Pharma Budgets Stabilize: Innovation and analytics budgets are opening, with Doximity already the top choice for AI spend among surveyed pharma buyers.
- Margin Structure Enables Aggressive Investment: High software margins support a dual mandate of growth and profitability, even as AI costs rise temporarily.
- SMB Pharma Penetration Grows: AI search and portal partnerships are expanding Doximity’s reach into underpenetrated smaller pharma brands.
Risks
AI adoption remains in early innings, and the timing of large-scale monetization is subject to customer ramp and budget cycles. Elevated AI compute and R&D spend may pressure margins if revenue scaling lags. Regulatory scrutiny around clinical AI accuracy and patient data privacy is intensifying, with emerging litigation and hospital risk committees likely to influence purchasing. Macro headwinds in pharma marketing budgets, though stabilizing, could still constrain near-term growth if conditions worsen.
Forward Outlook
For Q2 2027, Doximity guided to:
- Revenue of $170–$171 million (1% YoY growth at midpoint)
- Adjusted EBITDA of $80.5–$81.5 million (48% margin midpoint)
For full-year 2027, management raised guidance to:
- Revenue of $671–$681 million (5% growth at midpoint)
- Adjusted EBITDA of $309–$329 million (47% margin midpoint)
Management highlighted:
- Q2 faces a tough prior-year comparison, with more substantial AI search revenue recognized in Q3 and beyond.
- AI investment will remain elevated to meet clinician demand and expand product capabilities, with gross margins expected in the mid to high 80% range.
Takeaways
Doximity’s Q1 results underscore a successful pivot from AI promise to tangible platform leverage, with usage, client engagement, and commercial momentum all trending upward.
- AI-Driven Platform Expansion: Rapid clinician adoption of AI tools is deepening workflow integration and enhancing Doximity’s value proposition to both hospitals and pharma.
- Enterprise and SMB Opportunity: Cross-segment traction, including new SMB pharma wins, is diversifying revenue streams and reducing reliance on large accounts.
- Second-Half Acceleration Watch: Investors should monitor AI search revenue ramp and continued hospital adoption as leading indicators for sustained growth and operating leverage in FY28.
Conclusion
Doximity enters the AI era with strong platform fundamentals, clear commercial validation, and a disciplined approach to scaling both usage and monetization. The company’s ability to maintain high margins while investing aggressively in clinical AI positions it for durable leadership as healthcare digitization accelerates.
Industry Read-Through
Doximity’s quarter signals a major shift in digital health and pharma marketing, as AI moves from pilot phase to enterprise-scale adoption. The rapid clinician uptake of AI scribe and search tools highlights growing physician comfort with digital workflow augmentation. Hospitals and health systems are increasingly seeking integrated, privacy-compliant AI partners, which could disadvantage point solution vendors. For pharma, the emergence of AI innovation and analytics budgets suggests that digital marketing leaders with trusted platforms and clinical credibility will capture a disproportionate share of new spend. Other health tech and SaaS players should note the operational discipline and margin preservation that underpin Doximity’s ability to fund innovation, setting a benchmark for sustainable AI investment across the sector.